Search
for

    Sort by

    Research 931–960 of 1000+

    1. Hereditary Vitamin D Resistant Rickets: Clinical, Laboratory, and Genetic Characteristics of 2 Iranian Siblings 2017 · 5 citations
    2. [Acceptability, tolerance and quality of life impact of cyproterone acetate treatment in female hirsutism. Comparison of 2 protocols in combination with oral or transdermal estradiol]. PubMed · 1994 · 4 citations
    3. hsa_circ_0002980 prevents proliferation, migration, invasion, and epithelial-mesenchymal transition of liver cancer cells through microRNA-1303/cell adhesion molecule 2 axis Aging · 2023 · 3 citations
    4. Alopecia areata. Diagnostic and therapeutic recommendations of the Polish Society of Dermatology. Part 2: Treatment Przegląd Dermatologiczny · 2023 · 1 citations
    5. Biotin beware: Perils of biotin supplementation: Response to: “The epidemiology, impact, and diagnosis of micronutrient nutritional dermatoses. Part 2: B-complex vitamins” Journal of the American Academy of Dermatology · 2022 · 1 citations
    6. Clinical Efficacy of a Topical Compounded Formulation in Male Androgenetic Alopecia: Minoxidil 10%, Finasteride 0.1%, Biotin 0.2%, and Caffeine Citrate 0.05% Hydroalcoholic Solution. PubMed · 2020 · 1 citations
    7. Plum-Blossom Needle Tapping combined with Ginger Juice Rubbing as an effective therapy for preventing hair loss in female obese patients after metabolic bariatric surgery: A 6-month 2×2 factorial design research protocol v1 2026
    8. Natural Sweetener Stevioside‐Based Dissolving Microneedles Solubilize Minoxidil for the Treatment of Androgenic Alopecia (Adv. Healthcare Mater. 2/2026) Advanced Healthcare Materials · 2026
    9. Efficacy and safety of topical GT20029 in male patients with androgenetic alopecia: a multicenter, randomized, double-blind, placebo-controlled phase 2 study Journal of Dermatological Treatment · 2025
    10. Efficacy and safety of topical GT20029 in male patients with androgenetic alopecia: a multicenter, randomized, double-blind, placebo-controlled phase 2 study 2025
    11. BindingDB Entry 50021519: Discovery of (2S)-N-(6-Cyano-5-(trifluoromethyl)pyridin-3-yl)-3-(6-(4-cyanophenyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)-2-hydroxy-2-methylpropanamide as a Highly Potent and Selective Topical Androgen Receptor Antagonist for Androgenetic Alopecia Treatment. 2025
    12. Efficacy and safety of topical GT20029 in male patients with androgenetic alopecia: a multicenter, randomized, double-blind, placebo-controlled phase 2 study 2025
    13. Referee report. For: Exploring the use of phytotherapy in benign prostatic hyperplasia [BPH]: a systematic review [version 1; peer review: 2 approved with reservations] Faculty of 1000 Research Ltd · 2025
    14. A Case of a 50-Year-Old Female with Dermatomyositis Secondary to a Paraneoplasm (Infiltrating Ductal Carcinoma, Grade 2) Journal of dermatology research reviews & reports · 2024
    15. Referee report. For: Case Report: Extensive digital gangrene as a primary manifestation of late-onset systemic lupus erythematosus [version 2; peer review: 2 approved] Faculty of 1000 Research Ltd · 2024
    16. Discovery of (2<i>S</i>)-<i>N</i>-(6-Cyano-5-(trifluoromethyl)pyridin-3-yl)-3-(6-(4-cyanophenyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)-2-hydroxy-2-methylpropanamide as a Highly Potent and Selective Topical Androgen Receptor Antagonist for Androgenetic Alopecia Treatment Journal of Medicinal Chemistry · 2023
    17. Referee report. For: Case Report: Tuberculosis lymphadenitis with systemic lupus erythematosus in a young woman: a case report [version 2; peer review: 2 approved, 1 not approved] Faculty of 1000 Research Ltd · 2023
    18. Referee report. For: Effect of Aloe vera extract in post-burn skin repair in rats [version 3; peer review: 2 approved, 1 not approved] Faculty of 1000 Research Ltd · 2023
    19. Referee report. For: Case Report: Tuberculosis lymphadenitis with systemic lupus erythematosus in a young woman: a case report [version 2; peer review: 1 approved, 1 approved with reservations, 1 not approved] Faculty of 1000 Research Ltd · 2023
    20. Referee report. For: Case Report: Tuberculosis lymphadenitis with systemic lupus erythematosus in a young woman: a case report [version 1; peer review: 2 approved with reservations, 1 not approved] Faculty of 1000 Research Ltd · 2023
    21. Referee report. For: Case Report: Tuberculosis lymphadenitis with systemic lupus erythematosus in a young woman: a case report [version 1; peer review: 2 approved with reservations] Faculty of 1000 Research Ltd · 2023
    22. Referee report. For: Practices, awareness, and perception towards home-based COVID-19 management among the general population in Mangalore city in south India [version 2; peer review: 1 approved, 1 approved with reservations] Faculty of 1000 Research Ltd · 2022
    23. Referee report. For: Practices, awareness, and perception towards home-based COVID-19 management among the general population in Mangalore city in south India [version 2; peer review: 2 approved] Faculty of 1000 Research Ltd · 2022
    24. Referee report. For: Case Report: Extensive digital gangrene as a primary manifestation of late-onset systemic lupus erythematosus [version 2; peer review: 1 approved] Faculty of 1000 Research Ltd · 2022
    25. Referee report. For: Phytochemicals With Anti 5-alpha-reductase Activity: A Prospective For Prostate Cancer Treatment [version 3; peer review: 2 approved] Faculty of 1000 Research Ltd · 2021
    26. Structure, atomic Hirshfeld surface, spectroscopic studies and magnetic and dielectric properties of new mixed solid solution (NH4 )2 Mn0.17 Cu0.83 Cl4 ⋅2H2 O Applied Organometallic Chemistry · 2019
    27. Referee report. For: Recent advances in treatment for Benign Prostatic Hyperplasia [version 1; referees: 2 approved] Faculty of 1000 Research Ltd · 2015
    28. SF-066-4 線維芽細胞+血管内皮前駆細胞共培養シートを用いた新たな膵断端処理法の開発(膵-2,サージカルフォーラム,第110回日本外科学会定期学術集会) 日本外科学会雑誌 · 2010
    29. Abstracts Presented at 41st Annual, 9th International Conference of the Islamic Medical Association of North America and First Joint Conference with the Federation of Islamic Medical Associations (FIMA), July 31-August 2, 2008 Journal of the Islamic Medical Association of North America · 2008
    30. New product intros (finasteride/tadalafil (new combination); sutimlimab; human SARS-CoV-2 recombinant nanoparticle vaccine, adjuvanted with AS03; bupropion hydrochloride/dextromethorphan hydrobromide (new combination)) Drugs of Today · 2022